274 related articles for article (PubMed ID: 9316670)
21. Apomorphine in patients with Parkinson's disease.
Muguet D; Broussolle E; Chazot G
Biomed Pharmacother; 1995; 49(4):197-209. PubMed ID: 7669939
[TBL] [Abstract][Full Text] [Related]
22. Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations.
Baas H; Harder S; Bürklin F; Demisch L; Fischer PA
Clin Neuropharmacol; 1998; 21(2):86-92. PubMed ID: 9579293
[TBL] [Abstract][Full Text] [Related]
23. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Chase TN
Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
[TBL] [Abstract][Full Text] [Related]
24. Subcutaneous apomorphine in parkinsonian on-off oscillations.
Stibe CM; Lees AJ; Kempster PA; Stern GM
Lancet; 1988 Feb; 1(8582):403-6. PubMed ID: 2893200
[TBL] [Abstract][Full Text] [Related]
25. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
26. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease.
Vaamonde J; Luquin MR; Obeso JA
Mov Disord; 1990; 5(3):260-2. PubMed ID: 2388647
[TBL] [Abstract][Full Text] [Related]
27. An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease.
Müller T
Expert Opin Pharmacother; 2020 Oct; 21(14):1659-1665. PubMed ID: 32640853
[TBL] [Abstract][Full Text] [Related]
28. [Continuous subcutaneous infusion of apomorphine for the treatment of Parkinson's disease].
Drapier S; Vérin M
Rev Neurol (Paris); 2006 Oct; 162(10):1019-23. PubMed ID: 17028572
[TBL] [Abstract][Full Text] [Related]
29. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Grandas FJ; Sesar-Ignacio Á
Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
[TBL] [Abstract][Full Text] [Related]
30. Apomorphine can sustain the long-duration response to L-DOPA in fluctuating PD.
Nutt JG; Carter JH
Neurology; 2000 Jan; 54(1):247-50. PubMed ID: 10636162
[TBL] [Abstract][Full Text] [Related]
31. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
Blanchet PJ; Konitsiotis S; Chase TN
J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
[TBL] [Abstract][Full Text] [Related]
32. Apomorphine in the treatment of Parkinson's disease.
Hagell P; Odin P
J Neurosci Nurs; 2001 Feb; 33(1):21-34, 37-8. PubMed ID: 11233359
[TBL] [Abstract][Full Text] [Related]
33. Dopamine agonists in Parkinson's disease: a look at apomorphine.
Lees AJ
Fundam Clin Pharmacol; 1993; 7(3-4):121-8. PubMed ID: 8500783
[TBL] [Abstract][Full Text] [Related]
34. Apomorphine continuous stimulation in Parkinson's disease: receptor desensitization as a possible mechanism of reduced motor response.
Maggio R; Barbier P; Corsini GU
J Neural Transm Suppl; 1995; 45():133-6. PubMed ID: 8748618
[TBL] [Abstract][Full Text] [Related]
35. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up.
Kanovský P; Kubová D; Bareš M; Hortová H; Streitová H; Rektor I; Znojil V
Mov Disord; 2002 Jan; 17(1):188-91. PubMed ID: 11835461
[TBL] [Abstract][Full Text] [Related]
36. Use of the dopamine agonist cabergoline in the treatment of movement disorders.
Marco AD; Appiah-Kubi LS; Chaudhuri KR
Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694
[TBL] [Abstract][Full Text] [Related]
37. Effective delivery of apomorphine in the management of Parkinson disease: practical considerations for clinicians and Parkinson nurses.
Bhidayasiri R; Chaudhuri KR; LeWitt P; Martin A; Boonpang K; van Laar T
Clin Neuropharmacol; 2015; 38(3):89-103. PubMed ID: 25970277
[TBL] [Abstract][Full Text] [Related]
38. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations.
Carbone F; Djamshidian A; Seppi K; Poewe W
CNS Drugs; 2019 Sep; 33(9):905-918. PubMed ID: 31473980
[TBL] [Abstract][Full Text] [Related]
39. Rapid treatment of "wearing off" in Parkinson's disease.
Swope DM
Neurology; 2004 Mar; 62(6 Suppl 4):S27-31. PubMed ID: 15037669
[TBL] [Abstract][Full Text] [Related]
40. Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations.
Widnell KL; Comella C
Mov Disord; 2005; 20 Suppl 11():S30-7. PubMed ID: 15822107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
